13F HOLDINGS REPORT
Wildcat Capital Management, LLC
Quarter ended Q3 2024 · Filed November 8, 2024 · Accession 0001839882-24-038436
Total Value
$204.6M
Positions
7
Other Managers
0
Confidential Omitted
No
Holdings (7)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | FRONTIER GROUP HLDGS INC | ULCC | 28,061,351 | $150.1M | 73.37% |
| 2 | RLX TECHNOLOGY INC | RLX | 18,046,195 | $32.7M | 15.96% |
| 3 | ALLOGENE THERAPEUTICS INC | ALLO | 2,920,787 | $8.2M | 4.00% |
| 4 | UROGEN PHARMA LTD | URGN | 495,606 | $6.3M | 3.08% |
| 5 | SKILLZ INC | SKLZ | 979,848 | $5.5M | 2.69% |
| 6 | KRONOS BIO INC | 50107A104 | 1,297,959 | $1.3M | 0.63% |
| 7 | SILEXION THERAPEUTICS CORP | SLXNW | 1,020,852 | $535,947 | 0.26% |